Prenetics' IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging

Launch Follows IM8's Record Growth to $6.6 Million Monthly Revenue in September

IM8 Accelerates Toward $100 Million ARR Milestone with One of the Industry's Fastest Growth Rates

Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the launch of Daily Ultimate Longevity from its rapidly scaling IM8 Health brand co-founded by David Beckham. Daily Ultimate Longevity is the first supplement scientifically formulated to comprehensively target all 12 hallmarks of aging, reinforcing IM8's position as one of the fastest-growing supplement brand in industry history. Since its full December 2024 launch, IM8 has achieved an extraordinary compound annual growth rate of 2,457%, with monthly revenue scaling from ~$600,000 to $6.6 million by September 2025, while serving approximately 350,000 customer purchases and delivering over 10 million servings. This unprecedented trajectory positions the brand to reach $100 million in annual recurring revenue within its first year of operations.

PLACEHOLDER

Unprecedented Market Performance Drives Innovation
Daily Ultimate Longevity represents the first supplement scientifically formulated to support all 12 hallmarks of aging as defined by landmark research published in the journal Cell (López-Otín et al., 2023) . Developed in collaboration with doctors and scientists from Mayo Clinic and the former Chief Scientist of NASA, the formulation features IM8's proprietary 5-Complex System, delivering therapeutic doses of premium, clinically-validated ingredients in an advanced powder format that provides 1,100% more active ingredient capacity than standard capsules, enabling a level of comprehensive support previously unattainable in a single product.

Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics / IM8, said, "Today's launch of the new advanced Daily Ultimate Longevity represents the culmination of our relentless pursuit to create the world's most advanced health optimization products." Danny further added, "As we approach our unprecedented $100 million annual recurring revenue milestone within our first year, this breakthrough formulation demonstrates why IM8 has achieved growth rates that are virtually unheard of in the industry. We're not just launching a product – we're defining an entirely new category in longevity science."

David Beckham, Co-Founder of IM8, said, "At IM8, our vision has always been to create the best quality products that really make a difference. I'm proud to see how the company's reputation has positively grown over the past year and excited that today we're launching Daily Ultimate Longevity to further expand our offering. I take it every morning with the Daily Ultimate Essentials drink – together, they taste great and give me the confidence that I'm supporting my health now, and for the future."

Revolutionary 5-Complex System Addresses Complete Aging Spectrum
Daily Ultimate Longevity's five synergistic complexes are clinically dosed to target key aging pathways including cellular senescence, mitochondrial dysfunction, and DNA repair—the same biological processes identified in the landmark Cell journal research defining the 12 Hallmarks of Aging:

  • Cellular Foundation Builder – Provides essential building blocks for cellular repair with 3,000 mg of glycine and 2,000 mg of taurine, doses shown in human studies to support sleep quality, metabolic health, and healthy lifespan.
  • Cellular Protection Activator (Senolytics) – Combines 250 mg trans-resveratrol, 250 mg quercetin, and 100 mg fisetin, three clinically studied compounds shown to help clear senescent cells and protect against oxidative damage.
  • NMN NAD⁺ Energy Booster – Features 300 mg pharmaceutical-grade nicotinamide mononucleotide (NMN) and 10 mg PQQ, the same combination and dosage range proven in multiple clinical trials to elevate NAD⁺ levels, enhance mitochondrial function, and promote cellular energy.
  • Metabolic AMPK/SIRT1 Activator – Includes 100 mg dihydroberberine, a next-generation form offering five times the bioavailability of standard berberine, along with 6 mg AstaPure® astaxanthin for metabolic and antioxidant support.
  • Cellular Renewal Activator (Autophagy) – Delivers 3 mg spermidine, the clinically recommended daily dose for individuals, promoting natural autophagy and cellular renewal for healthy aging.

Together, these five complexes form the first daily nutrition formula designed to comprehensively target all 12 Hallmarks of Aging, supported by human clinical research and tested for safety and purity.

Category-Defining Innovation in Rapidly Growing Market
The global longevity market is projected to reach $314 billion by 2030, driven by increasing consumer awareness of healthy aging and advances in longevity science. IM8's new advanced Daily Ultimate Longevity positions the company at the forefront of this expanding market with the industry's most comprehensive and scientifically advanced formulation.

"We created the most advanced longevity supplement on the market, featuring key ingredients like high-dose glycine and taurine, powerful senolytic compounds including quercetin and fisetin, NAD+ boosters NMN and PQQ, plus metabolic enhancers like dihydroberberine," said Dr. Darshan Shah, Board Certified Surgeon & Physician and IM8 Scientific Advisory Board member. "The five synergistic complexes of the new advanced Daily Ultimate Longevity target cellular senescence, one of the primary hallmarks of aging, while promoting comprehensive cellular energy support and DNA repair."

The powder format enables seamless integration with IM8's flagship Daily Ultimate Essentials, creating what the company calls the "Enhanced Beckham Stack" – a comprehensive daily health optimization routine that addresses both foundational nutrition and advanced longevity support in a single, convenient drink.

Premium Positioning with Proven Results
Daily Ultimate Longevity maintains IM8's commitment to premium quality with NSF certification (pending), vegan, non-GMO, gluten-free formulation free from all major allergens. Available exclusively at IM8health.com , it is priced at $149 for one-time purchase and $119 per month for subscription, reflecting its position as the most comprehensive and scientifically advanced longevity supplement available.

Strong Financial Foundation Supports Continued Innovation

Prenetics' strong financial position, with more than $90 million in liquid assets including ~$60 million in cash and 255.4 Bitcoin, valued at ~$31.6 million, provides a robust foundation for continued innovation and market expansion. The company remains debt-free with a clear path to profitability in early 2026.

For Media and Product Photos: Link

About Prenetics
Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer health. Our consumer initiative is led by IM8, one of the World's fastest growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a leading direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with its initial $20 million Bitcoin purchase and board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption. To learn more please visit www.prenetics.com and www.IM8health.com .

About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as co-founding partner and an elite team of scientists spanning medical professionals, academia, and space science. Combining cutting-edge science with nature's most potent ingredients, IM8 delivers a holistic, science-backed approach to health optimization. IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners. IM8 is a subsidiary of Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company dedicated to advancing consumer health.

Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us

Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com

Media Contact Jack Taylor PR im8@jacktaylorpr.com

Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Prenetics may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Prenetics' beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not to the following: the Company's ability to execute its strategies, manage its growth, and achieve and maintain profitability; the Company's ability to develop and commercialize its products and services; the Company's ability to maintain and enhance its brand; the Company's ability to compete effectively; the Company's ability to continue to develop and maintain relationships with its partners and customers; the Company's ability to protect its intellectual property; the Company's ability to comply with applicable laws and regulations; and the Company's ability to obtain additional financing. Further information regarding these and other risks is included in Prenetics' filings with the SEC. All information provided in this press release is as of the date of this press release, and Prenetics does not undertake any duty to update such information, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c511650-330b-413c-824e-f0c1de5c9ad5


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

PRE
The Conversation (0)
Cerrado Gold Announces Third Quarter 2026 Financial Results

Cerrado Gold Announces Third Quarter 2026 Financial Results

Highlights: Gold equivalent production of 16,985 Gold Equivalent Ounces ("GEO") at AISC of $1,546/oz Au during Q3 2026; Adjusted EBITDA of $33.8 million for Q3 2026 and $90.8 million year-to-date Earnings of US$0.04 per basic share outstanding in Q3 2026 and US$0.16 per share Year to Date,... Keep Reading...
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled

KELOWNA, BC / ACCESS Newswire / November 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, reports that final dosing has been completed on schedule with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral... Keep Reading...
OTC Markets

Small Cap Growth Virtual Investor Conference Agenda Announced for November 18th & 19th

Investors can hear from company executives, ask questions live and schedule 1x1 meetings with participating companies

NEW YORK, November 18, 2026 (GLOBE NEWSWIRE) — Virtual Investor Conferences (VIC), an OTC Markets Group Inc. property, today announced the agenda for the Small Cap Growth Virtual Investor Conference, taking place November 18th & 19th, 2026. The two-day event features company presentations across... Keep Reading...
Triple One Metals Appoints Andrew Gainsbury Chief Financial Officer

Triple One Metals Appoints Andrew Gainsbury Chief Financial Officer

Vancouver, British Columbia — November 18, 2026 — Triple One Metals Inc. ("Triple One" or the "Company") is pleased to announce the appointment of Andrew Gainsbury as Chief Financial Officer. Mr. Gainsbury has over 16 years of experience in financial management and consulting in both Canada and... Keep Reading...
Syntholene Energy Corp. Announces $3.5 Million Strategic Private Placement Led by Director and Co-Founder Canon Bryan

Syntholene Energy Corp. Announces $3.5 Million Strategic Private Placement Led by Director and Co-Founder Canon Bryan

Syntholene Energy Corp. (TSXV: ESAF) (FSE: 3DD0) (OTCQB: SYNTF) ("Syntholene" or the "Company") announced today that it intends to conduct a non-brokered private placement of units of the Company ("Units") at a price of $0.25 per Unit for gross proceeds of up to $3.5 million (the... Keep Reading...
AmeriTrust Announces Third Quarter 2026 Financial Results

AmeriTrust Announces Third Quarter 2026 Financial Results

Funded lease contract growth continued to accelerate in Q3 2026, with an increase of 80% in the value of contracts financed over Q2AmeriTrust Financial Technologies Inc. (TSXV: AMT,OTC:AMTFF) (OTCQB: AMTFF) (FSE: 1ZV) ("AmeriTrust", "AMT" or the "Company"), a fintech platform focused on... Keep Reading...
Juan Carlos Artigas.

Juan Carlos Artigas: Digital Gold’s Promise and its Trust Test

Digital gold promises to make gold ownership as easy as using an app. But will that convenience ultimately translate into broader adoption? Juan Carlos Artigas, the World Gold Council’s Americas CEO and global head of research, spoke with the Investing News Network about the sector’s potential... Keep Reading...
AmeriTrust Announces Change of Auditor

AmeriTrust Announces Change of Auditor

AmeriTrust Financial Technologies Inc. (TSXV: AMT,OTC:AMTFF) (OTCQB: AMTFF) (FSE: 1ZV) ("AmeriTrust", "AMT" or the "Company"), a fintech platform focused on automotive finance, today announced that at the request of the Company, HDCPA Professional Corporation (the "Predecessor Auditor") has... Keep Reading...
AmeriTrust Announces Warrant Exercise Proceeds of $35 Million

AmeriTrust Announces Warrant Exercise Proceeds of $35 Million

AmeriTrust Financial Technologies Inc. (TSXV: AMT,OTC:AMTFF) (OTCQB: AMTFF) (FSE: 1ZV) ("AmeriTrust", "AMT" or the "Company"), a fintech platform focused on automotive finance, announces that it has received gross proceeds of CAD$35,073,967 from the exercise of warrants.In January 2026,... Keep Reading...

Visa Expands Fan-First Strategy with New and Renewed Team Partnerships Across Pro Football

Visa's portfolio of 13 team relationships brings fans closer to pro football culture in some of the sport's most passionate markets Visa (NYSE: V), a global leader in digital payments, is building a fan-first pro football platform designed to connect more directly with fans, teams, communities,... Keep Reading...
AmeriTrust Auto Advances End-to-End Lease Remarketing Strategy

AmeriTrust Auto Advances End-to-End Lease Remarketing Strategy

TORONTO, ON / ACCESS Newswire / August 19, 2026 / AmeriTrust Financial Technologies Inc. (TSXV:AMT,OTC:AMTFF)(OTCQB:AMTFF)(Frankfurt:1ZV) ("AmeriTrust", "AMT" or the "Company"), a fintech platform focused on automotive finance, today announced that AmeriTrust Auto, a wholly owned subsidiary of... Keep Reading...

Interactive Chart

Latest Press Releases

Related News